Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Next Previous
Trial Profile

A Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Venetoclax (Primary) ; Chlorambucil; Obinutuzumab
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms GLOW
  • Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 22 Jan 2025 Planned End Date changed from 5 Apr 2027 to 5 Apr 2029.
  • 19 Nov 2024 According to a Johnson & Johnson media release, results from this study will be presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego from December 7-10.
  • 14 Jun 2024 According to Johnson & Johnson media release , the company announced publication of updated findings of this study which were featured in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #7009) in Chicago from 31 May - 4 June and as an encore presentation at the European Hematology Association (EHA) Congress in Madrid, Spain, from 13-16 June 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top